MCID: OPD006
MIFTS: 48

Opioid Addiction

Categories: Neuronal diseases

Aliases & Classifications for Opioid Addiction

MalaCards integrated aliases for Opioid Addiction:

Name: Opioid Addiction 25
Opiate Addiction 25 71
Opiate Dependence 25
Opioid Dependence 25

Classifications:



External Ids:

UMLS 71 C0524662

Summaries for Opioid Addiction

Genetics Home Reference : 25 Opioid addiction is a long-lasting (chronic) disease that can cause major health, social, and economic problems. Opioids are a class of drugs that act in the nervous system to produce feelings of pleasure and pain relief. Some opioids are legally prescribed by healthcare providers to manage severe and chronic pain. Commonly prescribed opioids include oxycodone, fentanyl, buprenorphine, methadone, oxymorphone, hydrocodone, codeine, and morphine. Some other opioids, such as heroin, are illegal drugs of abuse. Opioid addiction is characterized by a powerful, compulsive urge to use opioid drugs, even when they are no longer required medically. Opioids have a high potential for causing addiction in some people, even when the medications are prescribed appropriately and taken as directed. Many prescription opioids are misused or diverted to others. Individuals who become addicted may prioritize getting and using these drugs over other activities in their lives, often negatively impacting their professional and personal relationships. It is unknown why some people are more likely to become addicted than others. Opioids change the chemistry of the brain and lead to drug tolerance, which means that over time the dose needs to be increased to achieve the same effect. Taking opioids over a long period of time produces dependence, such that when people stop taking the drug, they have physical and psychological symptoms of withdrawal (such as muscle cramping, diarrhea, and anxiety). Dependence is not the same thing as addiction; although everyone who takes opioids for an extended period will become dependent, only a small percentage also experience the compulsive, continuing need for the drug that characterizes addiction. Opioid addiction can cause life-threatening health problems, including the risk of overdose. Overdose occurs when high doses of opioids cause breathing to slow or stop, leading to unconsciousness and death if the overdose is not treated immediately. Both legal and illegal opioids carry a risk of overdose if a person takes too much of the drug, or if opioids are combined with other drugs (particularly tranquilizers called benzodiazepines).

MalaCards based summary : Opioid Addiction, also known as opiate addiction, is related to opiate dependence and personality disorder. An important gene associated with Opioid Addiction is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Dopamine and Valproic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Related Diseases for Opioid Addiction

Diseases related to Opioid Addiction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 opiate dependence 31.3 OPRM1 OPRK1 OPRD1 DRD2
2 personality disorder 30.9 DRD2 COMT CCK
3 substance abuse 30.7 OPRM1 OPRK1 OPRD1 DRD2 COMT
4 polysubstance abuse 30.6 DRD2 COMT
5 alcohol use disorder 30.5 OPRM1 DRD2 COMT
6 heroin dependence 30.3 OPRM1 OPRD1 DRD2 COMT
7 social phobia 30.1 DRD2 COMT CCK
8 cocaine dependence 30.1 OPRM1 OPRK1 OPRD1 DRD2 COMT
9 cannabis dependence 30.1 DRD2 COMT ABCB1
10 eating disorder 30.0 OPRM1 DRD2 COMT CCK
11 amnestic disorder 30.0 OPRM1 OPRK1 OPRD1 DRD2
12 cyclothymic disorder 30.0 DRD2 COMT
13 trigeminal neuralgia 30.0 OPRM1 OPRK1 OPRD1
14 tobacco addiction 30.0 OPRM1 DRD2 CYP2B6 COMT
15 substance dependence 30.0 OPRM1 OPRK1 OPRD1 DRD2 COMT
16 morphine dependence 29.9 OPRM1 OPRK1 OPRD1 CCK
17 opioid abuse 29.9 PNOC OPRM1 OPRK1 OPRD1 DRD2 CCK
18 mood disorder 29.8 MAPK1 GRIN2A DRD2 COMT
19 withdrawal disorder 29.8 PNOC OPRM1 OPRK1 OPRD1 DRD2
20 constipation 29.7 OPRM1 OPRK1 OPRD1 CCK
21 drug dependence 29.7 PNOC OPRM1 OPRK1 OPRD1 DRD2
22 obsessive-compulsive disorder 29.7 GRIN2A DRD2 COMT CCK
23 panic disorder 29.7 DRD2 COMT CCKBR CCKAR CCK
24 pain agnosia 29.5 PNOC OPRM1 OPRK1 OPRD1 CCK
25 psychotic disorder 29.5 OPRM1 GRIN2A DRD2 COMT CCK
26 disease of mental health 29.5 OPRM1 OPRK1 OPRD1 GRIN2A DRD2 COMT
27 attention deficit-hyperactivity disorder 29.4 OPRM1 GRIN2A DRD2 COMT ABCB1
28 diarrhea 29.3 OPRM1 OPRK1 OPRD1 CYP2B6 CCK ABCB1
29 major depressive disorder 29.2 OPRM1 GRIN2A DRD2 CYP2B6 COMT ABCB1
30 neonatal abstinence syndrome 29.1 PNOC OPRM1 OPRK1 OPRD1 CYP2B6 COMT
31 pertussis 28.8 OPRM1 MAPK3 MAPK1
32 anxiety 28.5 PNOC OPRM1 OPRK1 GRIN2A DRD2 COMT
33 fibromyalgia 28.4 PNOC OPRM1 OPRK1 OPRD1 GRIN2D DRD2
34 alcohol dependence 28.3 PNOC OPRM1 OPRK1 OPRD1 GRIN2A DRD2
35 migraine with or without aura 1 27.7 VIPR2 PNOC OPRM1 OPRK1 OPRD1 DRD2
36 autism 27.4 VIPR2 OPRM1 MAPK3 GRIN3B GRIN2D GRIN2A
37 schizophrenia 27.1 VIPR2 OPRM1 GRIN3B GRIN2D GRIN2A DRD2
38 opioid dependence 1 12.7
39 chronic pain 10.6
40 tardive dyskinesia 10.4 DRD2 COMT
41 kleptomania 10.3 OPRK1 DRD2
42 cocaine abuse 10.3
43 drug psychosis 10.3 DRD2 COMT
44 cannabis abuse 10.3 OPRM1 DRD2 COMT
45 drug-induced mental disorder 10.3 DRD2 COMT
46 spinocerebellar ataxia 23 10.3 OPRM1 OPRK1 OPRD1
47 impulse control disorder 10.3 OPRM1 DRD2 COMT
48 trigeminal nerve disease 10.3 OPRM1 OPRK1 OPRD1
49 acalculous cholecystitis 10.3 CCKAR CCK
50 avoidant personality disorder 10.3

Comorbidity relations with Opioid Addiction via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Major Depressive Disorder Osteoporosis

Graphical network of the top 20 diseases related to Opioid Addiction:



Diseases related to Opioid Addiction

Symptoms & Phenotypes for Opioid Addiction

MGI Mouse Phenotypes related to Opioid Addiction:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 ABCB1 CCKAR CCKBR COMT DRD2 GRIN2A
2 endocrine/exocrine gland MP:0005379 10 ABCB1 CCK CCKAR CCKBR COMT DRD2
3 homeostasis/metabolism MP:0005376 10 ABCB1 CCK CCKAR CCKBR COMT DRD2
4 digestive/alimentary MP:0005381 9.92 ABCB1 CCKAR CCKBR DRD2 MAPK1 MAPK3
5 integument MP:0010771 9.65 CCKBR DRD2 GRIN2A GRIN2D MAPK1 MAPK3
6 nervous system MP:0003631 9.44 ABCB1 CCK CCKAR CCKBR COMT DRD2

Drugs & Therapeutics for Opioid Addiction

Drugs for Opioid Addiction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
3
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
4
Ribavirin Approved Phase 4 36791-04-5 37542
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
7
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
8
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
9
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
10
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
11
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
12
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
13
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
14
Tapentadol Approved Phase 4 175591-23-8 9838022
15
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
16
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
17
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
18
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
19
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
20
Trichostatin A Experimental Phase 4 58880-19-6
21 Nicotinic Agonists Phase 4
22 Cholinergic Agents Phase 4
23 Pharmaceutical Solutions Phase 4
24 Immunologic Factors Phase 4
25 Interferon-alpha Phase 4
26 Interferon alpha-2 Phase 4
27 interferons Phase 4
28 Tea Phase 4
29 Dopamine agonists Phase 4
30 Ketorolac Tromethamine Phase 4
31 Neurotransmitter Agents Phase 4
32 Adrenergic Agents Phase 4
33 Anti-Infective Agents Phase 4
34 Excitatory Amino Acid Antagonists Phase 4
35 Hormones Phase 4
36 Anticonvulsants Phase 4
37 Anti-Anxiety Agents Phase 4
38 Anesthetics Phase 4
39 Antitubercular Agents Phase 4
40 Anti-Bacterial Agents Phase 4
41 Antibiotics, Antitubercular Phase 4
42 Antimetabolites Phase 4
43 Calcium, Dietary Phase 4
44 calcium channel blockers Phase 4
45 Anesthetics, Local Phase 4
46 Lipid Regulating Agents Phase 4
47 Hypolipidemic Agents Phase 4
48
dipyrone Phase 4 522325
49
Heroin Phase 4 5462328
50 Antiviral Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 522)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
2 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
3 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
4 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
5 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
6 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
7 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
8 An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
9 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
10 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
11 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
12 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
13 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
14 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
15 A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
16 A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219 Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
17 Feasibility Study of Take-Home LAAM Medication Completed NCT00000300 Phase 4 LAAM
18 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
19 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Completed NCT00007527 Phase 4 naloxone;buprenorphine
20 A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
21 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
22 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
23 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
24 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
25 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
26 CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
27 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
28 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
29 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
30 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
31 Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine: A Four-phase Cross-over Study in Healthy Subjects. Completed NCT01854489 Phase 4 Placebo;Rifampicin;Buprenorphine
32 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
33 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
34 Pain Control in the Nuss Procedure: A Prospective, Randomized Trial of Cryoanalgesia vs. Thoracic Epidural Completed NCT02721017 Phase 4 Thoracic epidural (ropivicaine, fentanyl)
35 Use of Liposomal Bupivacaine for Postoperative Pain Management After Arthroscopic Rotator Cuff Repair Completed NCT03149887 Phase 4 Liposomal bupivacaine;Placebo
36 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
37 A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings Completed NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
38 Long Acting Naltrexone for Opioid Addiction: the Importance of Mental, Physical and Societal Factors for Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
39 Buprenorphine Extended-release in Jail and at Re-entry: Open-label Randomized Controlled Trial vs. Daily Sublingual Buprenorphine-naloxone Recruiting NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
40 Optimizing Patient Centered-Care: A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse (OPTIMA Trial) Recruiting NCT03033732 Phase 4 Methadone;Buprenorphine-Naloxone
41 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
42 Houston Emergency Opioid Engagement System (HEROES) Recruiting NCT03396276 Phase 4 Suboxone
43 RCT of Gabapentin Versus Placebo for Postoperative Pain After Sacrospinous Ligament Fixation for Pelvic Organ Prolapse Recruiting NCT03123861 Phase 4 Gabapentin;Placebo oral capsule
44 Efficacy of Metamizole Versus Ibuprofen and a Short Educational Intervention Versus Standard Care in Acute and Subacute Low Back Pain: A Randomized, Factorial Trial Recruiting NCT04111315 Phase 4 Metamizole Sodium;Ibuprofen 600 mg
45 Safety and Efficacy of Pre-emptive Tapentadol vs Pregabalin in Post Operative Pain Following Unilateral Total Knee Arthroplasty- A Randomised, Double Blind, Active Control, Clinical Trial Recruiting NCT03604354 Phase 4 Tapentadol 100 MG Oral Tablet;Pregabalin 150mg
46 A Randomized Clinical Trial of Single Dose Liposomal Bupivacaine Delivered Via VATS Intercostal Nerve Block vs. Continuous Bupivacaine Infusion Delivered Via Indwelling Subscapular Catheter After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
47 Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery Recruiting NCT03893734 Phase 4 methadone;Hydromorphone
48 Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic Active, not recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
49 Biomarkers of Disease and Response to Treatment in Opioid Addiction Active, not recruiting NCT02324725 Phase 4 Naltrexone
50 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Active, not recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol

Search NIH Clinical Center for Opioid Addiction

Genetic Tests for Opioid Addiction

Anatomical Context for Opioid Addiction

MalaCards organs/tissues related to Opioid Addiction:

40
Brain, Testes, Cortex, Liver, Prefrontal Cortex, Amygdala, Bone

Publications for Opioid Addiction

Articles related to Opioid Addiction:

(show top 50) (show all 1962)
# Title Authors PMID Year
1
Stigmatization of opioid addiction based on prescription, sex and age. 61
32447236 2020
2
Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010-2018. 61
32353575 2020
3
Chemogenetic modulation of accumbens direct or indirect pathways bidirectionally alters reinstatement of heroin-seeking in high- but not low-risk rats. 61
31747681 2020
4
Effects of tobacco on affect and craving during opioid addiction recovery: An ecological momentary assessment study. 61
32151893 2020
5
M3 but not M4 muscarinic receptors in the rostromedial tegmental nucleus are involved in the acquisition of morphine-induced conditioned place preference. 61
32534071 2020
6
Stereotyping and the opioid epidemic: A conjoint analysis. 61
32422524 2020
7
Predictive Modeling of Opioid Overdose Using Linked Statewide Medical and Criminal Justice Data. 61
32579159 2020
8
Dextromethorphan and bupropion reduces high level remifentanil self-administration in rats. 61
32246985 2020
9
Amitifadine, a triple reuptake inhibitor, reduces self-administration of the opiate remifentanil in rats. 61
32125484 2020
10
Corrigendum: Glutamatergic Systems and Memory Mechanisms Underlying Opioid Addiction. 61
32482846 2020
11
Reducing Health-Related Stigma Through Narrative Messages. 61
31014112 2020
12
Who is HOT and who is LOT? Detailed characterization of prescription opioid-induced changes in behavior between 129P3/J and 129S1/SvlmJ mouse substrains. 61
31489753 2020
13
Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder. 61
32563846 2020
14
The opioid epidemic in pediatrics: a 2020 update. 61
32371640 2020
15
The Opioid Epidemic: Challenge to Military Medicine and National Security. 61
32077961 2020
16
Opioid training development: Cultivating nurse competence through education. 61
32506588 2020
17
Nicotine and Opioids: a Call for Co-treatment as the Standard of Care. 61
32495248 2020
18
Evaluation of 19 short tandem repeat markers for individualization of Papaver somniferum. 61
32381242 2020
19
Opioid Overdose and Addiction Treatment: A Collaborative Model of Compassion, Patience, and Respect. 61
32396267 2020
20
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity. 61
31913038 2020
21
Addiction Treatment Capacity in Health Centers: The Role of Medicaid Reimbursement and Targeted Grant Funding. 61
32438889 2020
22
Depletion of the Microbiome Alters the Recruitment of Neuronal Ensembles of Oxycodone Intoxication and Withdrawal. 61
32341122 2020
23
Prospective Randomized Study Examining Preoperative Opioid Counseling on Postoperative Opioid Consumption after Upper Extremity Surgery. 61
32432491 2020
24
The impact of an innovative pharmacist-led inpatient opioid de-escalation intervention in post-operative orthopedic patients. 61
32421837 2020
25
Perioperative Management of Patients on Buprenorphine and Methadone: A Narrative Review. 61
32407063 2020
26
Murine model of OPRM1 A118G alters oxycodone self-administration and locomotor activation, but not conditioned place preference. 61
31778689 2020
27
Higher anhedonia during withdrawal from initial opioid exposure is protective against subsequent opioid self-administration in rats. 61
32388620 2020
28
The Raphe Dopamine System Controls the Expression of Incentive Memory. 61
32145184 2020
29
Glutamatergic Systems and Memory Mechanisms Underlying Opioid Addiction. 61
32341068 2020
30
Self-Help Groups And Medication Use In Opioid Addiction Treatment: A National Analysis. 61
32364856 2020
31
Opium-Related Lead Toxicity: An Integrative Review and Case Series. 61
32414545 2020
32
[Pregabalin and risk of addiction: A new care issue?] 61
32471706 2020
33
Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease. 61
32255722 2020
34
The internet market for Kratom, an opioid alternative and variably legal recreational drug. 61
32182543 2020
35
Overcoming Heroin Addiction without the Use of Pharmaceuticals: A Qualitative Interview Study. 61
32306887 2020
36
Effects of oxycodone on sensitivity to reinforcement magnitude: implications for effects of opioids on impulsive and risky choice. 61
31922965 2020
37
Effects of Compound 511 on BDNF-TrkB Signaling in the Mice Ventral Tegmental Area in Morphine-Induced Conditioned Place Preference. 61
32323150 2020
38
Implications of Drug Use Disorders on Spine Surgery. 61
31926361 2020
39
D1- but not D2-like dopamine receptor antagonist in the CA1 region of the hippocampus reduced stress-induced reinstatement in extinguished morphine-conditioning place preference in the food-deprived rats. 61
32040018 2020
40
Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease. 61
32259777 2020
41
The impact of chronic liver disease in patients receiving active pharmacological therapy for opioid use disorder: One-year findings from a prospective cohort study. 61
32088589 2020
42
Long-term treatment retention in West Virginia's comprehensive opioid addiction treatment (COAT) program. 61
32058182 2020
43
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series. 61
32207385 2020
44
Implementing an Unfolding Case Study Throughout the Nursing Curriculum to Increase Opioid Addiction Education. 61
32243558 2020
45
Case Report: Buprenorphine Induction Using Transdermal Buprenorphine in a Veteran With Opioid Use Disorder and Psychosis, Managing Precipitated Withdrawal. 61
32314788 2020
46
New Approaches to Pain Management. 61
32111271 2020
47
The role of the gut microbiome in opioid use. 61
31895059 2020
48
Prevalence and Risk Factors of Nonmedical Prescription Opioid Use Among Transgender Girls and Young Women. 61
32176305 2020
49
How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users. 61
32209533 2020
50
Army Liposome Formulation (ALF) family of vaccine adjuvants. 61
32228108 2020

Variations for Opioid Addiction

Expression for Opioid Addiction

Search GEO for disease gene expression data for Opioid Addiction.

Pathways for Opioid Addiction

Pathways related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 VIPR2 PNOC OPRM1 OPRK1 OPRD1 MAPK3
2
Show member pathways
13.02 VIPR2 PNOC OPRM1 OPRK1 OPRD1 GRIN3B
3
Show member pathways
12.47 MAPK3 MAPK1 GRIN3B GRIN2D GRIN2A DRD2
4
Show member pathways
12.27 MAPK3 MAPK1 CCKBR CCK
5 12.2 GRIN3B GRIN2D GRIN2A DRD2
6
Show member pathways
12.11 GRIN2D GRIN2A CCKBR CCKAR
7 11.97 MAPK3 MAPK1 GRIN2D GRIN2A
8
Show member pathways
11.78 GRIN3B GRIN2D GRIN2A DRD2
9
Show member pathways
11.77 CYP2B6 COMT ABCB1
10 11.67 MAPK3 MAPK1 DRD2
11
Show member pathways
11.59 MAPK3 MAPK1 GRIN2D GRIN2A DRD2
12
Show member pathways
11.51 CYP2B6 COMT ABCB1
13 11.5 VIPR2 MAPK3 MAPK1 GRIN3B GRIN2D GRIN2A
14 11.49 MAPK3 MAPK1 GRIN2D GRIN2A
15 11.26 GRIN3B GRIN2D GRIN2A
16 11.21 MAPK3 MAPK1 ABCB1
17 10.94 GRIN3B GRIN2D GRIN2A
18 10.84 MAPK3 MAPK1
19 10.77 MAPK3 MAPK1
20 10.69 CCKBR CCK
21 10.68 MAPK3 MAPK1
22 10.64 MAPK3 MAPK1

GO Terms for Opioid Addiction

Cellular components related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.42 VIPR2 OPRM1 OPRK1 OPRD1 MAPK3 MAPK1
2 integral component of membrane GO:0016021 10.34 VIPR2 OPRM1 OPRK1 OPRD1 GRIN3B GRIN2D
3 integral component of plasma membrane GO:0005887 10.03 VIPR2 OPRM1 OPRK1 OPRD1 GRIN2D GRIN2A
4 cell GO:0005623 10.02 OPRK1 MAPK3 MAPK1 GRIN2D GRIN2A DRD2
5 synapse GO:0045202 10.01 PNOC OPRK1 GRIN3B GRIN2D GRIN2A DRD2
6 axon GO:0030424 9.89 OPRM1 MAPK1 DRD2 COMT CCK
7 dendrite GO:0030425 9.88 PNOC OPRM1 OPRK1 DRD2 COMT CCK
8 postsynaptic membrane GO:0045211 9.77 OPRD1 GRIN3B GRIN2D GRIN2A COMT
9 integral component of postsynaptic membrane GO:0099055 9.7 OPRM1 OPRK1 DRD2
10 postsynaptic density membrane GO:0098839 9.69 GRIN3B GRIN2D GRIN2A
11 axon terminus GO:0043679 9.62 PNOC OPRK1 OPRD1 DRD2
12 pseudopodium GO:0031143 9.57 MAPK3 MAPK1
13 integral component of presynaptic membrane GO:0099056 9.56 OPRM1 OPRK1 OPRD1 DRD2
14 perikaryon GO:0043204 9.55 OPRM1 OPRK1 MAPK1 DRD2 CCK
15 plasma membrane GO:0005886 9.5 VIPR2 PNOC OPRM1 OPRK1 OPRD1 MAPK3
16 spine apparatus GO:0097444 9.46 OPRM1 OPRD1
17 NMDA selective glutamate receptor complex GO:0017146 9.13 GRIN3B GRIN2D GRIN2A

Biological processes related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.18 VIPR2 PNOC OPRM1 OPRK1 OPRD1 MAPK1
2 cell surface receptor signaling pathway GO:0007166 10 VIPR2 MAPK3 MAPK1 CCKBR
3 response to drug GO:0042493 10 GRIN2A DRD2 COMT ABCB1
4 chemical synaptic transmission GO:0007268 9.98 PNOC OPRK1 MAPK1 GRIN2A
5 G protein-coupled receptor signaling pathway GO:0007186 9.97 VIPR2 PNOC OPRM1 OPRK1 OPRD1 DRD2
6 response to lipopolysaccharide GO:0032496 9.93 OPRM1 MAPK3 MAPK1 COMT
7 response to ethanol GO:0045471 9.87 OPRM1 OPRK1 GRIN2A DRD2
8 response to toxic substance GO:0009636 9.86 MAPK3 MAPK1 DRD2
9 axonogenesis GO:0007409 9.86 DRD2 CCKAR CCK
10 locomotory behavior GO:0007626 9.86 OPRM1 OPRK1 DRD2
11 neuropeptide signaling pathway GO:0007218 9.84 PNOC OPRM1 OPRK1 OPRD1
12 response to estrogen GO:0043627 9.83 OPRK1 MAPK1 COMT
13 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.83 OPRM1 OPRK1 OPRD1
14 modulation of chemical synaptic transmission GO:0050804 9.81 GRIN3B GRIN2D GRIN2A DRD2
15 visual learning GO:0008542 9.8 GRIN2A DRD2 CCK
16 long-term synaptic potentiation GO:0060291 9.79 MAPK1 GRIN2D GRIN2A
17 response to cocaine GO:0042220 9.79 OPRM1 OPRK1 DRD2
18 synaptic transmission, glutamatergic GO:0035249 9.77 GRIN3B GRIN2D GRIN2A
19 response to morphine GO:0043278 9.75 OPRM1 OPRK1 DRD2
20 excitatory postsynaptic potential GO:0060079 9.73 OPRM1 GRIN2D GRIN2A DRD2
21 positive regulation of telomere capping GO:1904355 9.7 MAPK3 MAPK1
22 cellular response to dopamine GO:1903351 9.7 MAPK3 MAPK1
23 ionotropic glutamate receptor signaling pathway GO:0035235 9.7 GRIN3B GRIN2D GRIN2A
24 behavioral response to ethanol GO:0048149 9.69 OPRM1 DRD2
25 regulation of ossification GO:0030278 9.69 MAPK3 MAPK1
26 regulation of stress-activated MAPK cascade GO:0032872 9.68 MAPK3 MAPK1
27 excitatory chemical synaptic transmission GO:0098976 9.67 GRIN2D GRIN2A
28 Bergmann glial cell differentiation GO:0060020 9.67 MAPK3 MAPK1
29 outer ear morphogenesis GO:0042473 9.67 MAPK3 MAPK1
30 startle response GO:0001964 9.67 GRIN2D GRIN2A DRD2
31 regulation of early endosome to late endosome transport GO:2000641 9.66 MAPK3 MAPK1
32 positive regulation of macrophage proliferation GO:0120041 9.65 MAPK3 MAPK1
33 calcium ion transmembrane import into cytosol GO:0097553 9.65 GRIN2D GRIN2A
34 regulation of cellular pH GO:0030641 9.64 MAPK3 MAPK1
35 trachea formation GO:0060440 9.64 MAPK3 MAPK1
36 caveolin-mediated endocytosis GO:0072584 9.63 MAPK3 MAPK1
37 dopamine metabolic process GO:0042417 9.63 GRIN2A DRD2 COMT
38 regulation of Golgi inheritance GO:0090170 9.61 MAPK3 MAPK1
39 response to epidermal growth factor GO:0070849 9.6 MAPK3 MAPK1
40 cardiac neural crest cell development involved in heart development GO:0061308 9.58 MAPK3 MAPK1
41 sensory perception GO:0007600 9.58 PNOC OPRM1 OPRK1
42 cholecystokinin signaling pathway GO:0038188 9.56 CCKBR CCKAR
43 eating behavior GO:0042755 9.56 OPRM1 OPRK1 OPRD1 CCK
44 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.55 OPRM1 OPRK1
45 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.55 OPRM1 OPRK1 OPRD1 CCKBR CCKAR
46 opioid receptor signaling pathway GO:0038003 9.54 OPRM1 OPRK1 OPRD1
47 sensory perception of pain GO:0019233 9.35 OPRM1 OPRK1 MAPK3 MAPK1 GRIN2A
48 regulation of sensory perception of pain GO:0051930 9.1 OPRM1 OPRK1 OPRD1 GRIN2D COMT CCK

Molecular functions related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.98 VIPR2 OPRM1 OPRK1 OPRD1 DRD2 CCKBR
2 transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential GO:1904315 9.67 GRIN3B GRIN2D GRIN2A
3 peptide hormone binding GO:0017046 9.65 VIPR2 CCKBR CCKAR
4 ligand-gated ion channel activity GO:0015276 9.63 GRIN3B GRIN2D GRIN2A
5 glutamate receptor activity GO:0008066 9.54 GRIN3B GRIN2D GRIN2A
6 receptor serine/threonine kinase binding GO:0033612 9.52 OPRK1 OPRD1
7 glutamate-gated calcium ion channel activity GO:0022849 9.51 GRIN2D GRIN2A
8 neuropeptide binding GO:0042923 9.5 OPRM1 OPRK1 OPRD1
9 peptide binding GO:0042277 9.46 OPRM1 OPRK1 OPRD1 CCKAR
10 ionotropic glutamate receptor activity GO:0004970 9.43 GRIN3B GRIN2D GRIN2A
11 cholecystokinin receptor activity GO:0004951 9.4 CCKBR CCKAR
12 opioid receptor activity GO:0004985 9.13 OPRM1 OPRK1 OPRD1
13 NMDA glutamate receptor activity GO:0004972 8.8 GRIN3B GRIN2D GRIN2A

Sources for Opioid Addiction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....